Compare Revvity Inc (RVTY) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Taskus Inc — how do they compare? Revvity Inc trades at $110.7 (market cap $11.87B), while Taskus Inc trades at $5.86 (market cap $532.07M). The key difference: Revvity Inc is far larger — about 22.3× Taskus Inc's market cap, and Revvity Inc pays a 0.26% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| RVTY | TASK | |
|---|---|---|
Market Cap | $11.87B | $532.07M |
Sector | Technology | Technology |
52-Week High | $117.75 | $18.21 |
52-Week Low | $82.26 | $4.57 |
Enterprise Value | $14.36B | $927.77M |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
TaskUs (TASK) trades at $5.81, down 0.34% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 earnings of $0.35 per share, missing estimates, after beating in the prior two quarters. Revenue reached $1.18 billion in 2025 with net income of $102.28 million, showing strong profitability. Analysts maintain a consensus buy rating with a $9.50 price target, suggesting significant upside potential.
The stock appears undervalued with a P/E of 5.16 and P/S of 0.45, supported by robust ROE of 26.52%. Risks include recent earnings miss and competitive pressures in digital services. Positive cash flow and debt reduction trends provide fundamental strength, but investor sentiment is mixed amid technical overbought signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
